Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025

– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause of complications, morbidity and cost in dialysis patients – DURHAM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnolog ...